Zevra Therapeutics Inc (ZVRA) Stock Price, Quote & News

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 321 939 3416

Website: zevra.com

Address:

1180 Celebration Boulevard, Suite 103, Celebration, United States

Jhh3796 Jan. 31 at 2:17 PM

$ZVRA On 12/3/2025, 12/19/2025, and 1/12/2026, the shorts attempted to break below the 8 dollar mark. This is now a confirmed triple bottom on the daily. As of yesterday we broke and defended the 50 day MA again. If you look at the daily charts, we are attempting to form a W pattern which usually is Bullish overall. I've had to learn here to be sceptical but am optimistic for this year.

1 · Reply

KemPharm_rocks Jan. 31 at 1:48 AM

$ZVRA I sense this is getting old

0 · Reply

Magna141 Jan. 31 at 12:37 AM

$ZVRA Lets see, Crypto and Silver down. Green day on a Real Company that has Real EPS $0.59 and a Strong Group of Intelligent Investors focused on positive results.

1 · Reply

Jhh3796 Jan. 31 at 12:20 AM

$ZVRA Recent Patterns: Pop in the morning, traders take warning. Pop near close, positive goes....

0 · Reply

gc358 Jan. 30 at 10:11 PM

$ZVRA Let's see which insiders announced selling of restricted shares after hours: Quartell 4,533 Clifton 14,000 Thompson 4,080 Schafer 13,875 Sangiovanni 4,700 Any insiders buying? Bueller, Bueller?

2 · Reply

YouJackWagon Jan. 30 at 9:54 PM

$ZVRA my only stock that finished green today lol. This stock doesn’t give a flying fuck what the market is doing. Ever.

2 · Reply

WaynD01 Jan. 30 at 9:16 PM

$ZVRA As Q4 institutional holding filings started to show up we stand up at 79% tutes ownership. Vanguard increased its holding to 3,305,200 by 7%. Stratos wealth increased the position by 80% to 409K

1 · Reply

KemPharm_rocks Jan. 30 at 9:07 PM

$ZVRA institutional ownership at 79.14%

0 · Reply

WaynD01 Jan. 30 at 9:03 PM

$ZVRA When I posted this yesterday I did not expect that this will be proven next day. When all my other holdings low 5-10% ZVRA closed green!!

0 · Reply

ZacksResearch Jan. 30 at 3:00 PM

$ZVRA under $10 — beaten down or quietly setting up? 🤔 Shares are down 20.2% over the past 6 months, yet the stock is trading below its 5-year mean P/B of 3.87, even though it sits above the industry average. Earnings estimates for 2026 have stayed unchanged at 51 cents over the past 60 days — no cuts, no panic. Buy, sell, or hold from here? See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/ZVRA/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-31088&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_31088

1 · Reply

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Jan 15, 2026, 3:26 PM EST - 16 days ago

Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 3, 2026, 7:26 AM EST - 4 weeks ago

Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market

Dec 12, 2025, 4:30 PM EST - 7 weeks ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 2, 2025, 7:30 AM EST - 2 months ago

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Nov 20, 2025, 4:05 PM EST - 2 months ago

Zevra Therapeutics, Inc. Announces CFO Transition

Nov 5, 2025, 9:01 PM EST - 3 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 3 months ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Oct 29, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Oct 27, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Sep 18, 2025, 7:30 AM EDT - 4 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Sep 4, 2025, 7:30 AM EDT - 5 months ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 28, 2025, 7:30 AM EDT - 5 months ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 8:43 PM EDT - 6 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 7:30 AM EDT - 6 months ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Jul 28, 2025, 6:00 AM EDT - 6 months ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 18, 2025, 7:30 AM EDT - 7 months ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 16, 2025, 7:30 AM EDT - 7 months ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

May 29, 2025, 4:35 PM EDT - 8 months ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 21, 2025, 7:30 AM EDT - 9 months ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 13, 2025, 10:45 PM EDT - 9 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 9 months ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Apr 17, 2025, 7:30 AM EDT - 10 months ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 10 months ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 10 months ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 11 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 11 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 1 year ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 1 year ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 1 year ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 1 year ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 1 year ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 1 year ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 1 year ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 1 year ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 1 year ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Jhh3796 Jan. 31 at 2:17 PM

1 · Reply

KemPharm_rocks Jan. 31 at 1:48 AM

$ZVRA I sense this is getting old

0 · Reply

Magna141 Jan. 31 at 12:37 AM

$ZVRA Lets see, Crypto and Silver down. Green day on a Real Company that has Real EPS $0.59 and a Strong Group of Intelligent Investors focused on positive results.

1 · Reply

Jhh3796 Jan. 31 at 12:20 AM

$ZVRA Recent Patterns: Pop in the morning, traders take warning. Pop near close, positive goes....

0 · Reply

gc358 Jan. 30 at 10:11 PM

$ZVRA Let's see which insiders announced selling of restricted shares after hours: Quartell 4,533 Clifton 14,000 Thompson 4,080 Schafer 13,875 Sangiovanni 4,700 Any insiders buying? Bueller, Bueller?

2 · Reply

YouJackWagon Jan. 30 at 9:54 PM

$ZVRA my only stock that finished green today lol. This stock doesn’t give a flying fuck what the market is doing. Ever.

2 · Reply

WaynD01 Jan. 30 at 9:16 PM

1 · Reply

KemPharm_rocks Jan. 30 at 9:07 PM

$ZVRA institutional ownership at 79.14%

0 · Reply

WaynD01 Jan. 30 at 9:03 PM

$ZVRA When I posted this yesterday I did not expect that this will be proven next day. When all my other holdings low 5-10% ZVRA closed green!!

0 · Reply

ZacksResearch Jan. 30 at 3:00 PM

1 · Reply

lance1965 Jan. 30 at 2:42 PM

$ZVRA Maybe we get back into the $9's today!

4 · Reply

intowits Jan. 30 at 2:17 PM

$ZVRA TGIF!

2 · Reply

DevAd Jan. 30 at 2:15 PM

$ZVRA

0 · Reply

KemPharm_rocks Jan. 30 at 12:38 PM

$ZVRA “InvestorRelations_” has very poor investor relations 🤣

2 · Reply

InvestorRelations_ Jan. 30 at 10:28 AM

$ZVRA what a brutal start in 2026. Down 20k overall

1 · Reply

jemer Jan. 29 at 10:58 PM

$ZVRA Based on my research and keeping track of Zevra/Miplyffa hiring of new reps, how Ai is increasing discovery of NPC patients and reviewing posts on NPC Facebook Page, I believe that overall diagnosed NPC patients in US will be increased in the near term to 400+ from 350. Wouldn't surprise me if total patients will exceed 500 by end of 2026.

0 · Reply

WaynD01 Jan. 29 at 10:41 PM

$ZVRA @jemer @Rodzilla01 I am not Rod. but this is the only stock that is not giving me any anxiety from stuffs like company binary evemts, geopolitics, economics, market uncertainties, etc.

0 · Reply

jemer Jan. 29 at 10:19 PM

$ZVRA @Rodzilla01 Been trading in a very narrow range for almost 3 months. Curious to see Institutional numbers in the next few weeks. Rod....you still holding all shares with confidence? I am.

2 · Reply

Jhh3796 Jan. 29 at 6:45 PM

$ZVRA This stock is too obvious of manipulation. Large firms are playing with the price to help themselves and/or their friends to exit large short positions and re enter long at a discount. As long as we don't have an offering, the float will lead to a lock soon.

3 · Reply

intowits Jan. 29 at 3:05 PM

$ZVRA

0 · Reply

EthanStawk Jan. 29 at 12:59 PM

$ZVRA Wow.

1 · Reply

intowits Jan. 29 at 12:05 AM

$ZVRA 1.5 mil vol on down day.

1 · Reply

Market Cap	506.68M
Revenue (ttm)	23.61M
Net Income (ttm)	-105.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	17.46
Profit Margin	-446.89%
Debt to Equity Ratio	0.46

Volume	716,400
Avg Vol	1,062,976
Day's Range	N/A - N/A
Shares Out	56.30M
Stochastic %K	45%
Beta	1.08
Analysts	Strong Sell
Price Target	$22.86